Revelation Biosciences, Inc. (REVB) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Revelation Biosciences, Inc.
Address
4660 La Jolla Village Drive
San Diego, CA 92122
United States of America (the)
Phone
650 800 3717
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
November 17, 2020
Key Executives
| Name | Title | Pay | Year Born |
| James Rolke | Chairman & Chief Executive Officer | 884,641 | 1969 |
| Chester Stanley Zygmont | Chief Financial Officer & Corporate Secretary | 603,750 | 1980 |
| Sandra Vedrick | Vice President of Human Resources & Investor Relations | 0 | N/A |
| Carol Odle | Senior Director of Clinical Projects | 0 | N/A |
Description
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
